TRIO Pharmaceuticals

TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company developing a first-in-class antibody drug technology, TRAILBody™.

TRAILBody has the unique distinction of directly eliminating cancer cells without toxins or engaging immune cells and with no activity on normal cells thereby reducing toxicity.

TRIO is developing a specific TRAILBody to treat multiple myeloma in 1st line and relapsed refractory (RR) setting.